In addition, Qilu has 12 Subsidiaries...10 manufacturing sites, and over 23,000 employees Worldwide. Exports to 70 countries...with an R&D platform employing over 2000 scientists. They have launched over 300 products with 30 of the "First to Launch." Along with 20+ biosimilar products they are also over 200+ generic products. They have been recently awarded the "Best R&D Pipeline (August 2021) Pharmaceutical" company.
They are three areas of expertise:
__Innovative Oncology Programs (harkening back to SK's proclamations)
__Liver diseases Solutions
__Hiv Programs

Currently, there are 10 plus innovative projects that are in clinical stages...and ONE innovative Product that will be launched in 2022.
Qilu is a private company.